Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Surg Today. 2010 Sep;40(9):816-24. doi: 10.1007/s00595-009-4227-y. Epub 2010 Aug 26.
An intraductal papillary mucinous neoplasm (IPMN) is now a well-recognized disease entity. In general, the prognosis of IPMN is much more favorable than that of pancreatic ductal adenocarcinoma (PDAC). However, IPMN has a broad biological spectrum and it sometimes progresses, slowly showing neoplastic transformations. International consensus guidelines have been recently proposed for the management of IPMN. While they significantly contribute to appropriate management of IPMN, various issues including the natural history and malignant potential of IPMN are not fully elucidated. This review focuses on the malignant potential, including the postoperative recurrence of IPMN, coincidence of IPMN with PDAC, and extrapancreatic malignancy that may affect the long-term survival of the patients rather than IPMN itself.
导管内乳头状黏液性肿瘤（IPMN）现在是一种公认的疾病实体。一般来说，IPMN 的预后比胰腺导管腺癌（PDAC）要好得多。然而，IPMN 具有广泛的生物学谱，它有时会进展，缓慢地表现出肿瘤转化。最近提出了国际共识指南来管理 IPMN。虽然它们为 IPMN 的适当管理做出了重要贡献，但包括 IPMN 的自然史和恶性潜能在内的各种问题尚未完全阐明。这篇综述重点讨论了恶性潜能，包括 IPMN 的术后复发、与 PDAC 的并存以及胰腺外恶性肿瘤，这些都可能影响患者的长期生存，而不仅仅是 IPMN 本身。
